HLS reports Q1 2026 earnings: $12.9M revenue, 15% net sales growth in VASCEPA, and promising Nalemdo launch with $250K in first-month sales.

Key Takeaways

• Revenue for Q1 2026 reached $12.9 million, up 2% year-over-year.
• Adjusted EBITDA stood at $3.5 million, down from $3.8 million in Q1 2025 due to launch investments.
• Cash from operations surged 80% year-over-year, indicating improved operational efficiency.
• Net debt decreased by 52%, now standing at $31.9 million, strengthening the company’s financial position.
• The launch of Nalemdo saw nearly $250,000 in sales in its first month, indicating strong initial demand.

Financial Performance

In the first quarter of fiscal 2026, HLS reported revenue of $12.9 million, reflecting a 2% increase from $12.6 million in Q1 2025. This growth was primarily driven by a 15% increase in net sales of VASCEPA, marking the highest quarterly growth since Q2 last year. The company’s revenue stream was further bolstered by the appreciation of the Canadian dollar against the U.S. dollar.

Adjusted EBITDA for the quarter reached $3.5 million, down from $3.8 million in the same quarter the previous year. The decrease is attributed to increased commercial investments aimed at supporting the launch of Nalemdo. HLS anticipates that these launch-related expenses will primarily impact the first half of the year, with margins expected to improve in the latter half as revenue ramps up.

The balance sheet shows that cash from operations surged by 80% year-over-year, reflecting operational improvements and a significant reduction in interest expenses. As of March 31, 2026, HLS’s net debt was $31.9 million, down 52% from two years prior, enhancing the company's financial flexibility.

Strategic Initiatives

HLS is strategically focused on enhancing its cardiovascular portfolio, which has shown resilience and growth. The company has made significant strides in its operations, with VASCEPA continuing to grow in its seventh year on the market and Clozaril stabilizing after facing contracting dynamics in Ontario.

The recent launch of Nalemdo has been particularly promising. After its full commercial launch in April, Nalemdo generated nearly $250,000 in sales within the first month. The product is gaining traction, with multiple wholesalers placing reorders based on strong demand. Moreover, two major private payers in Canada, Canada Life and Sun Life, have begun listing Nalemdo with full coverage, which is expected to cover approximately 40% of privately insured patients in Canada.

In addition to Nalemdo, HLS is developing Nexlazette, a fixed-dose combination therapy expected to launch in the first half of 2027. This sequential launch strategy positions HLS to capitalize on synergies between the two products, extending its reach within the cardiovascular market and addressing unmet patient needs.

Future Outlook

Looking ahead, HLS has reaffirmed its 2026 revenue guidance of $56 to $60 million, reflecting mid-single-digit growth. Management expects adjusted EBITDA to range from $18.5 to $21 million, indicating relative stability as the company absorbs launch costs associated with Nalemdo. Significant growth in revenue is anticipated in the second half of the year as sales momentum increases.

The company is optimistic about Nalemdo and Nexlazette, with projections suggesting that these products could potentially double HLS’s revenues. The market opportunity is substantial, especially considering that approximately 5 to 6 million Canadians live with cardiovascular disease or elevated cardiovascular risk. HLS is targeting a defined subset of patients who do not achieve their LDL goals despite existing treatments.

Management highlighted that the recent changes in LDL cholesterol guidelines in Europe could also influence Canadian practices, potentially expanding the addressable patient population for HLS’s products. The anticipated growth trajectory positions HLS favorably as it prepares for new product launches and reimbursement negotiations.

In summary, HLS is strategically positioned to capitalize on its growing portfolio and expanding market opportunities. With a strengthened balance sheet, a robust pipeline of innovative products, and a clear focus on operational efficiency, HLS is well-equipped to drive growth in the coming years.

Overall, the company’s focus on cardiovascular therapeutics, coupled with its recent operational improvements and financial discipline, suggests a positive outlook for investors and stakeholders.

This analysis is based on public earnings call materials and is not investment advice.